Presence of KRAS mutations therefore represents a negative predictor of response to EGFR therapy and KRAS mutation testing has rapidly moved into the molecular diagnostic work-up of colorectal cancers considered for EGFR treatment [2,3]. The gene discussed is KRAS; the disease is colorectal cancer.